DJIA 18,010.68 -115.44 -0.64%
NASDAQ 5,070.03 -27.95 -0.55%
S&P 500 2,107.39 -13.40 -0.63%
market minute promo

ULTRAGENYX PHARMAC (NASDAQ: RARE)

87.00 -1.06 (-1.20%)

Quote as of


company name or ticker

Recent Quotes

RARE $87.00 -1.20%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $88.09
Previous Close $88.06
Daily Range $86.65 - $89.69
52-Week Range $32.36 - $89.69
Market Cap $3.1B
P/E Ratio -43.38
Dividend (Yield) $0.00 (0.0%)
Volume 346,808
Average Daily Volume 428,811
Current FY EPS -$2.53

Sector

Industry

ULTRAGENYX PHARMAC (RARE) Description

ULTRAGENYX PHARMAC Website: http://www.ultragenyx.com/

News & Commentary Rss Feed

Why Ultragenyx Pharmaceutical Inc. Stock Slumped

Ultragenyx shares aren't looking so "ultra" today after the company announced its intention to sell shares of common stock. Find out what this means for investors.

Ultragenyx Pharmaceutical's (RARE) CEO Emil Kakkis on Q1 2015 Results - Earnings Call Transcript

Can Catalyst Pharmaceutical Surprise this Earnings Season? - Analyst Blog

Alexion Puts Its Stock To Use At Last

Ultragenyx Announces Positive Data from Triheptanoin Study - Analyst Blog

Use Options For a Chance To Buy RARE at a 31% Discount

Ultragenyx Pharmaceutical (RARE): Strong Industry, Solid Earnings Estimate Revisions - Tale of the T

Ultragenyx Pharmaceutical (RARE): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape

UPDATE: MLV & Co Initiates Coverage On Ultragenyx Pharmaceutical On Positive Outlook

Ultragenyx Pharmaceutical's (RARE) CEO Emil Kakkis Discusses Q4 2014 Results - Earnings Call Transcr

Ultragenyx Pharmaceutical's (RARE) CEO Emil Kakkis Discusses Q4 2014 Results - Earnings Call Transcript

CRT Capital Initiates Coverage On Ultragenyx Pharmaceutical

Ultragenyx Offers Presentation of Disease Burden Data in Adult Patients with X-Linked Hypophosphatem

Ultragenyx Offers Presentation of Disease Burden Data in Adult Patients with X-Linked Hypophosphatemia

See More RARE News...